Research programme: Chk1 kinase inhibitors - Galapagos/Avantogen

Drug Profile

Research programme: Chk1 kinase inhibitors - Galapagos/Avantogen

Alternative Names: Chk1 kinase inhibitors research programme - BioFocus/Avantogen

Latest Information Update: 13 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avantogen; Galapagos NV
  • Class
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; HIV infections

Most Recent Events

  • 13 Apr 2007 No development reported - Preclinical for Cancer in United Kingdom (unspecified route)
  • 13 Apr 2007 No development reported - Preclinical for HIV infections treatment in United Kingdom (unspecified route)
  • 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top